(NASDAQ:AMGN) share price is up 22% in the last three years, that falls short of the market return. Disappointingly, the ...

Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 ...

On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.

On July 16, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock ...

BofA analyst Tim Anderson raised the firm’s price target on Amgen (AMGN) to $261 from $252 and keeps an Underperform rating on the shares. For Q2, ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with chemotherapy, according to interim data from a late-stage study.

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

Second-quarter earnings season remained top of mind Tuesday, with Coca-Cola and General Motors among those reporting.